Generate Biomedicines (NASDAQ:GENB) Coverage Initiated at Piper Sandler

Key Points

• Piper Sandler initiated coverage with an "overweight" rating and a $24.00 price target, implying roughly a 91.7% upside from the prior close.
• Other major firms (Guggenheim, Goldman Sachs, Morgan Stanley, Cantor Fitzgerald) also started coverage with mostly Buy/Overweight ratings and an average analyst target of $25.00; five analysts rate the stock a Buy.
• Shares opened at $12.52 (52‑week range $11.00–$15.32); Generate Biomedicines applies machine learning and generative AI to design therapeutic proteins, which analysts view as the catalyst for the projected upside.

Equities research analysts at Piper Sandler began coverage on shares of Generate Biomedicines (NASDAQ:GENB - Get Free Report) in a research note issued on Tuesday. The brokerage set an "overweight" rating and a $24.00 price target on the stock. Piper Sandler's price objective indicates a potential upside of 91.69% from the company's previous close.

GENB has been the topic of a number of other reports. Wall Street Zen upgraded shares of Generate Biomedicines to a "hold" rating in a report on Saturday, March 14th. Cantor Fitzgerald started coverage on Generate Biomedicines in a report on Tuesday. They issued an "overweight" rating on the stock. Guggenheim initiated coverage on Generate Biomedicines in a research note on Tuesday. They issued a "buy" rating and a $30.00 price target on the stock. Morgan Stanley began coverage on Generate Biomedicines in a report on Tuesday. They set an "overweight" rating and a $20.00 price target for the company. Finally, The Goldman Sachs Group began coverage on Generate Biomedicines in a report on Tuesday. They issued a "buy" rating and a $26.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $25.00.

Generate Biomedicines Price Performance

Shares of Generate Biomedicines stock opened at $12.52 on Tuesday. Generate Biomedicines has a 52-week low of $11.00 and a 52-week high of $15.32.

About Generate Biomedicines

Generate Biomedicines, Inc NASDAQ: GENB is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.